1 Department of Epidemiology School of Public Health University of Alabama at Birmingham AL.
2 Mount Sinai Heart Icahn School of Medicine at Mount Sinai New York NY.
J Am Heart Assoc. 2019 Jan 8;8(1):e010376. doi: 10.1161/JAHA.118.010376.
Background Prior studies suggest that persistence with and adherence to statin therapy is low. Interventions to improve statin persistence and adherence have been developed over the past decade. Methods and Results This was a retrospective cohort study of adults aged ≥21 y with commercial or government health insurance in the MarketScan (Truven Health Analytics) and Medicare databases who initiated statins in 2007-2014 and (1) started treatment after a myocardial infarction (n=201 573), (2) had diabetes mellitus but without coronary heart disease (CHD; n=610 049), or (3) did not have CHD or diabetes mellitus (n=2 244 868). Persistence with (ie, not discontinuing treatment) and high adherence to statin therapy were assessed using pharmacy fills in the year following treatment initiation. In 2007 and 2014, the proportions of patients persistent with statin therapy were 78.1% and 79.1%, respectively, among those initiating treatment following myocardial infarction; 66.5% and 67.3%, respectively, for those with diabetes mellitus but without CHD; and 64.3% and 63.9%, respectively, for those without CHD or diabetes mellitus. Between 2007 and 2014, high adherence to statin therapy increased from 57.9% to 63.8% among patients initiating treatment following myocardial infarction and from 34.9% to 37.6% among those with diabetes mellitus but without CHD (each P<0.001). Among patients without CHD or diabetes mellitus, high adherence did not improve between 2007 (35.7%) and 2014 (36.8%; P=0.14). In 2014, statin adherence was lower among younger, black, and Hispanic patients versus white patients and those initiating a high-intensity statin dosage. Statin adherence was higher among men and patients with cardiologist care following treatment initiation. Conclusions Persistence with and adherence to statin therapy remain low, particularly among those without CHD.
先前的研究表明,患者坚持并遵从他汀类药物治疗的比例较低。在过去十年中,已经开发出了改善他汀类药物坚持性和遵从性的干预措施。
这是一项回顾性队列研究,纳入了在 MarketScan(Truven Health Analytics)和 Medicare 数据库中具有商业或政府健康保险、年龄≥21 岁、于 2007-2014 年开始服用他汀类药物的成年人,他们(1)在心肌梗死(MI)后开始治疗(n=201573),(2)患有糖尿病但无冠心病(CHD;n=610049),或(3)无 CHD 或糖尿病(n=2244868)。通过治疗开始后一年内的药房配药情况来评估患者对他汀类药物治疗的坚持性(即未停药)和高遵从性。在 2007 年和 2014 年,分别有 78.1%和 79.1%的 MI 后开始治疗的患者坚持使用他汀类药物治疗;分别有 66.5%和 67.3%的有糖尿病但无 CHD 的患者坚持使用他汀类药物治疗;分别有 64.3%和 63.9%的无 CHD 或糖尿病的患者坚持使用他汀类药物治疗。在 2007 年至 2014 年期间,MI 后开始治疗的患者中,他汀类药物高遵从性从 57.9%增加到 63.8%,而有糖尿病但无 CHD 的患者从 34.9%增加到 37.6%(均 P<0.001)。在无 CHD 或糖尿病的患者中,2007 年(35.7%)和 2014 年(36.8%;P=0.14)之间他汀类药物高遵从性并未改善。在 2014 年,与白人患者和起始高剂量他汀类药物治疗的患者相比,年轻、黑人、和西班牙裔患者的他汀类药物依从性较低。与治疗开始后接受心脏病专家治疗的患者相比,男性和患者的他汀类药物依从性更高。
坚持和遵从他汀类药物治疗的比例仍然较低,特别是在无 CHD 的患者中。